Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Flare Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.flaretx.com/
Year Founded: 2021
Status: Private
See Emerging Company Profile .
BioCentury | Feb 13, 2025
Management Tracks
Lee joins Lycia as CMO
Plus: Firth joins Panacea, Lakewood appoints Manion chair and updates from Ai Proteins, Cognito and Kala
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | May 26, 2023
Data Byte
The 20 biggest venture raises year-to-date: genetic medicines dominate
Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines
BioCentury | Mar 31, 2023
Management Tracks
Amarin CEO Mikhail resigns, Kostas named chair
Plus: BioCryst appoints Hutson chair and updates from Flare, Mytide and TScan
BioCentury | Mar 22, 2023
Finance
March 22 Quick Takes: GordonMD, Pfizer Ventures lead Flare’s $123M B round
Plus: FDA approvals for Cidara, Incyte and updates from Karuna, Astellas, NImmune, AbbVie, Roche, Lilly
BioCentury | Jul 26, 2022
Management Tracks
Rakhit to succeed Third Rock’s Celniker at Flare
Plus Generate hires Goldman Sachs veteran Jason Silvers as CFO, and updates from HotSpot, Berkeley Lights and more
BioCentury | Jun 15, 2022
Data Byte
Third Rock’s penchant for platforms, product engines
The firm has backed 11 companies since the start of 2021; none are single-asset plays
BioCentury | Apr 26, 2022
Management Tracks
Stoffels becomes Galapagos board chairman
Plus Vedere Bio II and management moves at Jnana, Flare, DeepCure and more
BioCentury | Oct 26, 2021
Management Tracks
Immunomedics vet Itri takes CMO post at
Plus Mersana, Athira, Aprecia and more
BioCentury | May 15, 2021
Emerging Company Profile
Median seed, A round sizes have more than doubled since 2017
2021 is turning out to be a bumper year, in particular for start-ups with new modalities
Items per page:
1 - 10 of 11